Strategy
While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.
At the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor commented on the “offensively” low pricing for antibiotics in the US – “less than a packet of M&Ms” – while also revealing that the firm has struck a deal with a US PBM for its Samsung Bioepis-partnered Pyzchiva ustekinumab biosimilar to Stelara.
As Bob Bradway addressed the J.P. Morgan Healthcare Conference in San Francisco, the Amgen chief executive discussed the firm’s biosimilars business – including an ocrelizumab rival to Ocrevus that has just been added to its pipeline. Meanwhile, the CEO also outlined his expectations for imminent biosimilar competition to Amgen’s Prolia and Xgeva denosumab brands.
Viatris expressed confidence at the J.P. Morgan Healthcare Conference that it will hit its targets for complex injectables in 2025, while providing an update on its GLP-1 ambitions and its delinquent manufacturing facility in Indore, India.
In an exclusive interview with Generics Bulletin, Aspargo Labs CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.
AEON Biopharma says it is planning for a biosimilar biological product development type 2 meeting in 2025 for its proposed biosimilar to the world-famous Botox brand, after raising much-needed capital to keep it afloat in 2025.
Celebrating its first birthday as a transformed and integrated company, Biocon casts a wider net for its ustekinumab biosimilar.
Stada has made the strongest indication yet that it is preparing for an initial public offering, appointing Andreas Fibig as independent chairman of a board of directors that will be established “in the event of an IPO.”
In the final instalment of his three-part interview with Generics Bulletin, Sandoz CEO Richard Saynor talks about opportunities on the horizon, including GLP-1s, ADCs and oligonucleotides – and explains why he has no interest in pursuing value added medicines.
In the second part of our exclusive interview with Richard Saynor, the Sandoz CEO discusses the importance of both the small-molecule generics and biosimilars businesses for the company, talking about portfolio selection and specific product opportunities for biosimilars while also contrasting the firm’s European and US generics leadership aspirations and approaches to the business.
In the first instalment of a three-part interview with Richard Saynor, the Sandoz CEO talks about the aftermath of the company’s spinoff from former parent Novartis and the work still left to do; the increasing prominence of biosimilars for Sandoz; the firm’s investments in manufacturing; thoughts on the potential for significant M&A; and future opportunities for the industry leader.
GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.
Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.
Synthon’s current owners, BC Partners, are selling a controlling stake in the Dutch complex generics specialist to Goldman Sachs Asset Management.
Teva vows to make two of its inhalers more accessible in the US through charity Direct Relief, despite still being tangled up in a lawsuit with Amneal over ProAir HFA. Also, another inhaler maker GSK is scrutinized over its pricey authorized generic alternative.
Amid rumors that Stada is sounding out investors for an IPO valued at around €1.5bn – following suggestions earlier this year that the company was being shopped around to potential buyers – the German generics giant has acknowledged to Generics Bulletin that options under review could include a sale or IPO.
As ocrelizumab biosimilar entry is coming closer, Biogen hopes that development partner Genentech will protect the franchise with new Ocrevus products.
The divestment decision comes years after it slimmed down amid challenges in the Japanese generic market.
Coherus is fully exiting the biosimilars space after striking a final deal worth up to $558m to divest its Udenyca US pegfilgrastim franchise to Accord parent company Intas.
Celltrion Group chairman outlines new plans for the Korean biosimilars giant to move into the CDMO sector and updates on new drug development activities.